证券代码：300575 证券简称：中旗股份 公告编号：2025-020 江苏中旗科技股份有限公司 2024 年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股东会审议通过的权益分派方案情况 1、江苏中旗科技股份有限公司（以下简称"公司"），2024年度权益分派方 案已获2025年4月29日召开的2024年度股东会审议通过，具体内容为：以股本 464,756,400股为基数，每10股派送现金股利0.5元（含税），合计应派发现金股 利23,237,820.00元，不送红股，不以资本公积转增股本。利润分配预案发布后 至实施前，公司总股本如发生变化，将按照每股分配总额不变的原则，相应调 整分配比例。 2、自利润分配预案披露至实施期间，公司股本总额未发生变化。 3、本次实施的权益分派方案与股东会审议通过的预案及其调整原则一致。 四、权益分派对象 本次分派对象为：截止2025年5月15日下午深圳证券交易所收市后，在中国 证券登记结算有限责任公司深圳分公司（以下简称"中国结算深圳分公司"）登 记在册的本公司全体股东。 五、权益分派方法 1、本公司此 ...

证券代码：300575 证券简称：中旗股份 公告编号：2025-018 江苏中旗科技股份有限公司 2024 年度股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、会议召开和出席情况 江苏中旗科技股份有限公司（以下简称"公司"）2024年度股东会于2024年4月29 日下午2:30在江苏省南京玄武区苏园路6号江苏软件园2幢会议室召开。会议采取现场 投票和网络投票相结合的方式。 通过深圳证券交易所交易系统进行网络投票的时间为:2024 年 4 月 29 日 9:15～ 9:25、9:30～11:30、13:00～15:00；通过深圳证券交易所互联网投票系统进行投票的 具体时间为: 2024 年 4 月 29 日 9:15～15:00。 本次会议由公司董事会召集，公司董事长吴耀军先生主持，会议的召集、召开与 表决程序符合《中华人民共和国公司法》《深圳证券交易所创业板股票上市规则》等 有关法律法规、部门规章、规范性文件及《公司章程》的规定。 股东出席的总体情况：通过现场和网络投票的股东 249 人，代表股份 227,832,629 股，占公司有表决权 ...

证券代码：300575 证券简称：中旗股份 公告编号：2025-019 江苏中旗科技股份有限公司 关于 2025 年限制性股票激励计划内幕信息知情人及首次授予的激励对 象买卖公司股票情况的自查报告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 （一）核查对象为本激励计划的内幕信息知情人和首次授予的激励对象； （二）本激励计划的内幕信息知情人均填报了《内幕信息知情人登记表》； （三）公司向中国结算深圳分公司就核查对象在自查期间买卖公司股票情况进行 了查询确认，并由中国证券登记结算有限公司深圳分公司出具了《信息披露义务人持 股及股份变更查询证明》及《股东股份变更明细清单》。 二、核查对象买卖本公司股票的情况说明 根据中国结算深圳分公司出具的《信息披露义务人持股及股份变更查询证明》及 《股东股份变更明细清单》，在自查期间，合计 60 名核查对象（其中不存在内幕信息 知情人）存在买卖公司股票的情况，其余核查对象在上述期间内不存在买卖公司股票 的行为。具体情况如下： 1 （一）内幕信息知情人买卖公司股票的情况 在自查期间，未发现相关内幕信息知情人买卖公司股票的行为，也 ...

中国北京市朝阳区东三环中路 5 号财富金融中心 3、11、12 层 | 邮编:100020 3/11/12F Fortune Financial Center (FFC), No.5 Dong San Huan Zhong Road Chaoyang District, Beijing 100020, China Tel: +86 10 6502 8888 | Fax: +86 10 6502 8866 | www.hylandslaw.com 北京浩天律师事务所 关于江苏中旗科技股份有限公司 2024年度股东会的律师见证法律意见书 致：江苏中旗科技股份有限公司 北京浩天律师事务所（以下简称"本所"）接受江苏中旗科技股份有限公司 （以下简称"公司"）的委托，指派本所律师对公司2024年度股东会（以下简称 "本次股东会"）进行法律见证，并根据《中华人民共和国公司法》、《中华人民 共和国证券法》、《上市公司股东会规则》、《深圳证券交易所创业板股票上市规 则（2024年修订）》等现行法律、法规、规范性文件及《江苏中旗科技股份有限公 司章程》（以下简称"公司章程"）的有关规定出具本法律意见书。 本法律意见书仅供见证本 ...

Financial Performance - The company reported a basic earnings per share of -0.0700 yuan for Q1 2025, a decrease of 250% compared to -0.0200 yuan in Q1 2024, and a significant drop from 0.2000 yuan in Q1 2023 [1] - The net profit for Q1 2025 was -0.34 billion yuan, a decline of 240% from -0.1 billion yuan in Q1 2024, and a stark contrast to a profit of 0.93 billion yuan in Q1 2023 [1] - The operating revenue increased by 16.52% to 5.29 billion yuan in Q1 2025, compared to 4.54 billion yuan in Q1 2024, but decreased from 7.42 billion yuan in Q1 2023 [1] - The return on equity was -1.59% in Q1 2025, a significant decline from -0.46% in Q1 2024 and down from 4.43% in Q1 2023 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 84.16 million shares, accounting for 24.55% of the circulating shares, with a decrease of 3.87 million shares compared to the previous period [1] - Notable shareholders include Wu Yaojun with 33.98 million shares (9.91%), Wang Jie with 16.68 million shares (4.87%), and Guotai Jiatai Pension Product with 7.89 million shares (2.30%) [2] - New entrants among the top shareholders include Guotai Fund Management and China Bank, while several funds such as Jiashi Fund Management have exited the top ten list [2][3] Dividend Policy - The company has announced that it will not distribute dividends or transfer shares this time [4]

Financial Performance - The company's revenue for Q1 2025 was ¥529,298,407.37, representing a 16.54% increase compared to ¥454,174,060.88 in the same period last year[5] - The net loss attributable to shareholders was ¥34,102,227.34, a significant increase of 245.04% from a loss of ¥9,883,434.43 in the previous year[5] - The basic and diluted earnings per share were both -¥0.07, reflecting a 250.00% decline from -¥0.02 in the previous year[5] - Net profit for the period was a loss of ¥34,184,364.79, compared to a loss of ¥10,470,497.67 in the previous period, indicating a significant decline in profitability[19] - The total comprehensive income for the period was a loss of ¥34,184,364.79, compared to a loss of ¥10,470,497.67 in the previous period, reflecting worsening overall financial health[19] Cash Flow and Liquidity - The net cash flow from operating activities was negative at ¥46,537,549.48, a decrease of 142.82% compared to a positive cash flow of ¥108,675,167.33 in the same period last year[5] - Cash flow from operating activities showed a net outflow of ¥46,537,549.48, a stark contrast to a net inflow of ¥108,675,167.33 in the prior period[21] - The company’s cash and cash equivalents saw a net decrease of ¥85,271,144.70, a 937.65% increase in outflow compared to the previous year[8] - Cash and cash equivalents at the end of the period decreased to ¥284,147,118.61 from ¥364,248,185.33, a decline of approximately 22%[22] - Investment activities resulted in a net cash outflow of ¥57,836,732.77, slightly improved from a net outflow of ¥57,916,849.41 in the previous period[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,453,983,678.70, a slight increase of 0.95% from ¥4,412,257,969.81 at the end of the previous year[5] - Current assets totaled ¥1,859,442,851.92, up from ¥1,806,689,010.03 at the beginning of the period, reflecting a growth of approximately 2.8%[14] - Total liabilities amounted to ¥2,262,088,162.89, up from ¥2,188,500,688.78, representing a growth of about 3.4%[15] - Non-current assets decreased slightly to ¥2,594,540,826.78 from ¥2,605,568,959.78, a decline of approximately 0.4%[14] - The company's equity attributable to shareholders decreased by 1.50% to ¥2,090,414,909.08 from ¥2,122,194,536.87 at the end of the previous year[5] Expenses - The company reported a significant increase in sales expenses, which rose by 56.74% to ¥13,736,193.90 due to higher promotional and consulting costs[8] - Total operating costs increased to ¥555,416,189.11 from ¥461,724,648.54, representing a growth of approximately 20.2% year-over-year[18] - Research and development expenses rose to ¥19,024,755.17, up from ¥15,870,822.94, reflecting an increase of about 19.5%[18] - The company incurred financial expenses of ¥5,782,268.80, compared to a financial income of ¥4,027,041.62 in the previous period, indicating a shift in financial performance[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,304, with the largest shareholder holding 29.24% of the shares[9] - The net profit attributable to the parent company was not explicitly stated but can be inferred from the retained earnings of ¥1,241,271,901.80, down from ¥1,275,374,129.14, indicating a decrease of approximately 2.7%[15] - The company reported a decrease in employee compensation payable from ¥55,277,598.72 to ¥28,926,856.18, a reduction of about 47.7%[15] - The company maintained a stable capital reserve of ¥198,804,814.53, unchanged from the previous period[15]

证券代码：300575 证券简称：中旗股份 公告编号：2025-016 江苏中旗科技股份有限公司 薪酬与考核委员会关于 2025 年限制性股票激励计划首次授予激励 对象名单的核查意见及公示情况说明 公司于 2025 年 4 月 12 日在中国证监会创业板指定信息披露网站上公告了《江苏中 旗科技股份有限公司 2025 年限制性股票激励计划（草案）及摘要》《江苏中旗科技股份 有限公司 2025 年限制性股票激励计划实施考核管理办法》及《2025 年限制性股票激励计 划激励对象名单》等公告，并于 2025 年 4 月 12 日在公司公告栏公示了《2025 年限制性 股票激励计划激励对象名单》，对本次拟激励对象的姓名和职务进行了公示，公示时间 为 2025 年 4 月 12 日至 2025 年 4 月 21 日。截至本公告披露日，公司薪酬与考核委员会 未收到任何异议。 （二）关于公司薪酬与考核委员会对拟激励对象的核查方式 公司薪酬与考核委员会核查了本次拟激励对象的名单、身份证件、拟激励对象与公 司（含子公司）签订的劳动合同、拟激励对象在公司（含子公司）担任的职务。 二、薪酬与考核委员会核查意见 根据《管理办法》《公司 ...

Group 1: Company Performance and Financials - The company achieved operating revenue of ¥2,422,198,069.32, a year-on-year increase of 1.35% [4] - The net profit attributable to shareholders was ¥11,721,037.33, a significant decline of 93.88% compared to the previous year [4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥24,498,601.05, down 89.02% year-on-year [4] Group 2: Future Growth Drivers - Future profit growth will be driven by factors such as increased demand for traditional green and environmentally friendly products, continuous process upgrades, and new project construction at production bases [1] - The company aims to expand its international market presence through "going global" strategies [1] Group 3: Industry Trends and Challenges - The pesticide industry is expected to transform towards greening, intelligence, and globalization, with a growing demand for high-efficiency, low-toxicity biopesticides [2] - The industry is experiencing structural changes due to international agricultural market fluctuations and stricter environmental policies [3] Group 4: Impact of External Factors - The company exports a low percentage of its products to the U.S., thus the impact of the U.S.-China tariff war is expected to be limited [2] - The company faces risks from raw material price fluctuations, environmental protection regulations, and safety production risks [8][9] Group 5: Product Development and Innovation - The company is focusing on the development of innovative pesticides, including FG001 and FG201, which are expected to have significant market potential [5][6] - FG001 is designed to effectively control major weeds in rice fields, while FG201 is a novel SDHI fungicide with a broad spectrum of efficacy [6] Group 6: Market Expansion and Risk Management - The company is committed to optimizing procurement management to mitigate risks associated with raw material supply and price volatility [8] - Measures are in place to manage exchange rate risks due to a significant portion of sales being denominated in U.S. dollars [9]

Summary of Conference Call Records Company and Industry Overview - The conference call discusses a company in the agricultural chemicals industry, specifically focusing on the production and sales of pesticides and herbicides. The company is navigating changes in sales models and production capacity for the year 2024 and beyond. Key Points and Arguments Financial Performance - The company reported a significant decrease in cash flow from operating activities, with amounts of 575 million and 643 million for the third and fourth quarters respectively, attributed to changes in sales models and increased domestic sales [1][1][1] - The profit contributions by quarter were as follows: Q1 showed a loss, Q2 contributed over 50 million in net profit, Q3 had a loss of over 14 million, and Q4 reported a loss of 4 million [1][1][1] - The overall sales cost and financial situation for 2024 are expected to remain stable, with no significant changes anticipated [3][3][3] Production Capacity and Utilization - The company has a production capacity utilization rate of 74.34% for raw materials and intermediates, and 84% for technical products, indicating a healthy production environment [2][2][2] - New projects are underway, including the expansion of production capacity for various products, which are expected to be completed by 2025 and 2026 [3][3][3] Research and Development - Continuous investment in R&D is emphasized, particularly in new textile drugs and innovative pharmaceuticals, with expectations of launching promising products in the future [4][4][4] - The company is focusing on developing new herbicides and has plans for multiple product launches in the coming years [6][6][6] Market Position and Pricing Strategy - The company holds a significant market share but is cautious about pricing strategies, indicating that the timing for price adjustments has not yet arrived [2][2][2] - The pricing environment is expected to stabilize, with indications that 2025 will be a more positive year compared to 2024 [8][8][8] Future Outlook - The company anticipates that 2025 will see improved performance compared to 2024, with expectations of higher production and sales volumes [5][5][5] - The introduction of new products and the stabilization of prices are expected to enhance profitability and market position [14][14][14] - The company is also exploring international markets and aims to expand its product offerings beyond domestic markets [26][26][26] Challenges and Risks - The company faces challenges related to fluctuating raw material prices and the need for regulatory approvals for new products, which may impact timelines for product launches [24][24][24] - There is a recognition of the competitive landscape in the agricultural chemicals sector, with a focus on maintaining quality and innovation to differentiate from competitors [9][9][9] Additional Important Content - The company is committed to a "second entrepreneurship" strategy aimed at achieving high growth rates and enhancing shareholder returns [17][17][17] - The management acknowledges the importance of effective communication with investors and stakeholders to build trust and transparency [27][27][27] This summary encapsulates the key insights from the conference call, highlighting the company's current performance, strategic initiatives, and future outlook within the agricultural chemicals industry.

证券代码：300575 证券简称：中旗股份 公告编号：2025-015 江苏中旗科技股份有限公司 关于 2024 年度股东大会增加临时提案暨股东大会补充通知的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 经江苏中旗科技股份有限公司（以下简称"公司"）第四届董事会第五次会议审议通 过，公司决定于 2025 年 4 月 29 日召开 2024 年度股东大会。具体内容详见公司于 2025 年 3 月 31 日在巨潮资讯网（www.cninfo.com.cn）披露的《关于召开 2024 年度股东大会 通知的公告》。 2025 年 4 月 11 日，公司第四届董事会第六次会议审议通过了《公司 2025 年限制性 股票激励计划（草案）及摘要的议案》《公司 2025 年限制性股票激励计划实施考核管理 办法的议案》以及《关于提请股东大会授权董事会办理公司 2025 年限制性股票激励计划 有关事项的议案》，此议案尚需提请公司股东大会审议。为提高决策效率，持有公司 3% 以上股份的股东吴耀军先生于 2025 年 4 月 11 日向公司董事会提交了《关于提请 2024 年 ...